In 2017, Cell reported that the combination of oncolytic virus T-VEC and PD-1 anti-tumor drug Keytruda was used to treat melanoma (Ribas et al., 2017), setting off an upsurge of research on oncolytic virus combined therapy. This evidence concerns the gene PDCD1 and neoplasm.